The Short Version
A question I am being asked more frequently by patients is whether GLP-1 receptor agonist medications are associated with vision loss.
The short answer is that the evidence is mixed and still developing.
Some well-designed studies have identified an association between these medications and a rare eye condition called NAION. Other large observational studies have not found a statistically significant increase in risk. Australian and international regulators have reviewed the emerging evidence, and warnings about NAION have now been added to Australian Product Information across the GLP-1 receptor agonist class.
The absolute risk remains low.
This article explains what NAION is, what the research has found so far, and what the current clinical advice means for people who have been prescribed these medications.
What Is NAION?
NAION stands for non-arteritic anterior ischaemic optic neuropathy.
It is a sudden, usually painless loss of vision caused by reduced blood flow to the optic nerve. It typically affects one eye and, in some cases, the vision loss can be permanent. There is currently no proven treatment that reliably reverses the damage once it occurs, which is why recognising the symptoms and seeking prompt assessment matters.
NAION itself is uncommon, but several of its established risk factors are also common in people living with metabolic disease. These include type 2 diabetes, hypertension, obesity, sleep apnoea and vascular disease.
That overlap is important.
When the people taking a medication already have some of the same characteristics associated with the condition being studied, working out whether the medication itself contributes additional risk becomes considerably more complicated than simply comparing two numbers.
Symptoms associated with NAION can include sudden, painless loss of vision in one eye, a dark or missing patch in the visual field, blurring, or waking with a new blind spot or shadow in one eye.
Those symptoms warrant urgent eye assessment.
Not a routine appointment made for next week.
Urgent assessment, the same day if possible.
Why This Became A Clinical Conversation
In 2023, neuro-ophthalmologists at Massachusetts Eye and Ear in Boston noticed a possible pattern among patients presenting with NAION who had been prescribed semaglutide.
That observation prompted a formal investigation, with the results published in JAMA Ophthalmology in 2024.
The study attracted considerable attention because it identified an association large enough to warrant further investigation. It also prompted additional studies using different populations and data sources, some of which supported the original signal and some of which did not.
Since then, regulatory agencies have reviewed observational studies, post-market safety reports and other available evidence.
The important point is that this did not begin with proof that one thing caused the other.
It began with a signal.
The work since then has been about determining how meaningful that signal is.
What The Research Has Found
The Original Massachusetts Eye And Ear Study
Hathaway and colleagues published one of the first widely discussed studies on this question in JAMA Ophthalmology in 2024.
It was a retrospective, single-centre study examining patients assessed at the Massachusetts Eye and Ear neuro-ophthalmology service between 2017 and 2023.
The study included 710 patients with type 2 diabetes and 979 patients who had overweight or obesity.
Among the patients studied, those prescribed semaglutide had a higher observed rate of NAION than patients prescribed comparison medications. The association was seen in both the diabetes group and the overweight or obesity group.
Those findings appropriately generated clinical attention.
They also need to be interpreted in context.
This was a retrospective observational study conducted at a specialist neuro-ophthalmology centre, meaning the population was not representative of everybody taking these medications. The number of NAION events was relatively small. And, importantly, an observational association does not establish that the medication caused the condition.
That distinction matters.
The Danish-Norwegian Cohort
A much larger study by Simonsen and colleagues used national health registry data from Denmark and Norway to examine the same question in people with type 2 diabetes.
The researchers compared people initiating semaglutide with people initiating another class of diabetes medication.
After adjustment for relevant risk factors, semaglutide use was associated with a higher rate of NAION in the study population.
The pooled hazard ratio was 2.81.
That sounds striking, and relative risk figures often do.
But the absolute number of events remained small. Only 32 NAION events occurred across the combined cohorts, and the study authors emphasised that the absolute risk remained low.
That distinction between relative and absolute risk is important whenever rare adverse events are discussed.
A large relative increase in a very uncommon event can still represent a small absolute risk for an individual patient.
Studies That Have Not Found The Same Association
Not every study has reproduced that result.
A large 2025 study using the TriNetX database examined patients across multiple countries and did not identify a statistically significant increase in NAION among the groups studied.
Other observational analyses and reviews have also contributed to a broader evidence base that remains inconsistent.
There are several possible reasons different studies reach different conclusions.
The populations are different.
The comparison groups are different.
The way NAION is identified in medical records is different.
The underlying health of the patients is different.
And observational research always has the difficult job of separating the effect of a medication from the characteristics that led someone to need that medication in the first place.
So a study finding an association does not automatically prove causation.
Equally, a study failing to find a statistically significant association does not prove that no risk exists.
That is why the regulatory review matters.
The Australian Regulatory Picture
In July 2026, the Therapeutic Goods Administration published a safety update following its review of the potential association between GLP-1 receptor agonists and NAION.
The TGA described NAION as a rare but serious eye disorder that may result in permanent visual impairment.
Its review found that the available evidence was conflicting.
The Advisory Committee on Medicines considered that the available evidence may support a safety signal for semaglutide specifically, while the evidence was less supportive for some other medicines in the class.
Following its overall review, the TGA introduced updated safety information across the GLP-1 receptor agonist class in Australia.
For semaglutide, the Australian Product Information now notes that some epidemiological studies indicate an increased risk of NAION during treatment and advises urgent ophthalmological assessment if sudden vision loss occurs.
Cases of NAION have also been reported with other medicines with GLP-1 receptor agonist activity, which is reflected in updated Australian safety information.
This is an important development because regulatory warnings are not the same thing as proving that every reported event was caused by the medicine.
They mean there is enough information to justify making clinicians and patients aware of the potential risk.
The Honest Clinical Picture
The evidence is not perfectly neat.
That is normal.
Some observational studies have identified an association between semaglutide and NAION. Other large studies have not found a statistically significant increase. Australian regulators have reviewed the broader evidence and concluded that the signal warrants additional warnings and clinical awareness.
At the same time, NAION remains rare.
Those two facts can exist together.
It is possible for a potential adverse effect to be clinically important enough to discuss while still being unlikely to happen to any individual patient.
What I do not think is helpful is treating this as either a reason for panic or a reason for dismissal.
The appropriate response is awareness.
Know what the symptoms look like.
Know that sudden vision loss is not something to monitor at home for a few days.
And if you have concerns about your individual risk, discuss them with the clinician managing your treatment rather than making changes based on a headline or a social media post.
Who Should Be Particularly Aware?
NAION has a number of established risk factors, including diabetes, hypertension, sleep apnoea, obesity and cardiovascular disease.
Several of those conditions are also common among people prescribed GLP-1 receptor agonist medications.
That does not mean someone with one of these conditions will develop NAION.
It means individual risk is more complicated than whether somebody takes one particular medication.
Anatomy also matters. The TGA’s updated Australian Product Information notes that people with a particular anatomical appearance of the optic nerve, sometimes called a “disc at risk”, are at higher underlying risk of developing NAION. This is something that can be assessed by an optometrist or ophthalmologist.
If you have been prescribed a GLP-1 receptor agonist and have concerns about your eye health or existing risk factors, that is a reasonable conversation to have with your treating clinician.
What matters more urgently is knowing what to do if your vision suddenly changes.
What To Do If You Notice Changes In Your Vision
Sudden changes in vision need prompt assessment regardless of whether you are taking a particular medication.
If you experience any of the following, seek urgent medical or eye assessment:
- Sudden loss of vision in one eye, even if it is only partial
- A new dark patch or missing area in your visual field
- Waking with blurred vision, a shadow or a blind spot in one eye that was not there previously
- A sudden change in side or peripheral vision in one eye
These symptoms are not specific to NAION.
There are other causes of sudden vision loss, including conditions where urgent assessment is particularly important.
The point is not to diagnose yourself.
The point is not to wait.
What Does The Absolute Risk Mean?
This is where conversations about rare side effects can become confusing.
A study might report that the relative risk of an event is two or three times higher in one group.
That sounds dramatic.
But you also need to know how frequently the event occurs in the first place.
In the Danish cohort, for example, the observed rate of NAION remained only a few cases per 10,000 person-years.
European regulators have also classified NAION as a very rare adverse effect in relation to semaglutide, meaning the absolute number of people affected is small.
That does not make the condition unimportant.
Permanent vision loss is significant regardless of how uncommon it is.
But patients deserve both sides of the number: an understanding that the potential consequence is serious and an understanding that the event itself is uncommon.
Risk makes more sense when you discuss it in absolute terms.
Should You Stop Your Medication?
Not simply because you have read about NAION.
Questions about continuing or changing prescription treatment need to be considered in the context of why the medication was prescribed, how you are responding to it, your existing health conditions and your individual risk factors.
If you are taking a GLP-1 receptor agonist and are worried about this research but have no new visual symptoms, discuss the concern with your prescribing clinician.
If you experience sudden or partial vision loss, however, seek urgent medical assessment.
That is not something to defer until your next routine appointment.
Australian safety information now specifically advises urgent ophthalmological assessment when sudden vision loss occurs.
This article provides general health information and does not replace individual medical advice. Decisions about prescription medicines, including whether to continue or change treatment, should be made with the clinician responsible for your care. If you experience sudden or partial vision loss, seek urgent medical assessment.
Looking Forward
The evidence around NAION and GLP-1 receptor agonists will continue to develop as further research and pharmacovigilance data become available.
For now, I think the most useful approach is the same one we should take whenever medicine safety evidence is evolving.
Acknowledge what we know.
Be clear about what we do not.
Keep the absolute risk in perspective.
And make sure patients know which symptoms should never be ignored.
The research does not support panic.
It does support awareness.
And when an individual treatment decision needs to be made, that decision belongs in a clinical conversation where the potential risks, benefits and the person’s broader health can all be considered together.
Evidence Notes
Therapeutic Goods Administration. (2026). GLP-1 RAs and rare vision disorder. Australian Government Department of Health, Disability and Ageing.
Hathaway, J.T., Shah, M.P., Hathaway, D.B., Zekavat, S.M., et al. (2024). Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmology, 142(8), 732–739. https://doi.org/10.1001/jamaophthalmol.2024.2296
Simonsen, E., Lund, L.C., Ernst, M.T., et al. (2025). Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study. Diabetes, Obesity and Metabolism, 27(6), 3094–3103. https://doi.org/10.1111/dom.16316
The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy. American Journal of Ophthalmology. 2025.
European Medicines Agency. (2025). Pharmacovigilance Risk Assessment Committee review of the potential association between semaglutide and non-arteritic anterior ischaemic optic neuropathy.
